Clinical Study Synopsis

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Clinical Study Synopsis"

Transcription

1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer HealthCare Pharmaceuticals Inc. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer HealthCare Pharmaceuticals Inc. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayerhealthcare.com apply to the contents of this file.

2 Clinical Trial Results Synopsis Study Design Description Study Sponsor: Bayer HealthCare Pharmaceuticals Inc. Study Number: (XA0801) NCT Study Phase: IV (Prospective Non-Interventional) Test Product Official Study Title: XAMOS - Xarelto in the prophylaxis of post-surgical venous thromboembolism after elective major orthopedic surgery of hip or knee Therapeutic Area: CV Risk Management Name of Test Product: Name of Active Ingredient: Dose and Mode of Administration: Rivaroxaban (Xarelto, BAY ) Rivaroxaban Non-interventional study (NIS): dose of drug and mode of administration solely at the discretion of the attending physician (recommended dose according to the summary of product characteristics of Xarelto 10 mg film coated tablet: 10 mg rivaroxaban taken orally once daily) Reference Therapy/Placebo Reference Therapy: Standard of care: any other pharmacological treatment for VTE (venous thromboembolism) prophylaxis (e.g. Fondaparinux, Lowmolecular-weight-heparins [LMWH], vitamin K antagonists [VKA]) Dose and Mode of Administration: Non-interventional study: dose of drug and mode of administration solely at the discretion of the attending physician. Duration of Treatment: Non-interventional study: duration of treatment solely at the discretion of the attending physician Studied period: Date of first subjects first visit: 18 Feb 2009 Date of last subjects last visit: 01 Feb 2013 XAMOS was an international non-interventional study conducted in 39 countries worldwide. The results from the first worldwide analysis (i.e. analysis conducted for European Medicines Agency (EMA)) included 17,701 enrolled patients from 37 countries that were in the database until 18-Aug-2011 (data lock point for EMA analysis). This analysis will be referred to as worldwide analyses in this document. End of enrollment for the EMA analysis was the 3-Feb Three countries (Korea, Philippines and Switzerland) could continue to enroll new patients after this date. In addition, two countries (India and Vietnam) started enrollment after February All patients from those 5 countries which could not be locked on 18-Aug-2011 or which were enrolled after 3-Feb-2011 are referred to as patients post locked. This synopsis summarizes also the analyses for all post locked patients which will be referred to as post EMA in this document. Premature Study Suspension / Termination: Not applicable Page 1 of 6

3 Substantial Study Protocol Amendments: There was one protocol amendment dated 16 Sep 2009 during the course of the study which was generated for the sites in Switzerland. In Switzerland, rivaroxaban was indicated not only for elective hip or knee replacement, but also for any major surgery of the lower limbs. Therefore, the amendment primarily changed the inclusion criteria, allowing the inclusion of patients with any major lower limb surgery to be included into the study. In Switzerland the concept of non-interventional studies according to EU Directive 2001/20/EC does not exist. Therefore, XAMOS-SWISS was conducted as an interventional Phase IV study as agreed with Swissmedic. Study Center(s): For EMA analysis: 260 investigational sites in 37 countries: 252 sites enrolled patients: Australia (5), Austria (5), Belgium (6), Bosnia & Herzegovina (2), Canada (3), Chile (1), China (19), Colombia (5), Cyprus (3), Czech Republic (8), Denmark (4), Finland (5), France (20), Germany (32), Greece (7), Hong Kong (2), Hungary (5), Italy (19), Korea (17), Latvia (2), Lebanon (2), Lithuania (6), Macedonia (3), Mexico (5), Netherlands (15), Norway (3), Philippines (1), Portugal (2), Serbia (3), Singapore (2), Slovakia (5), Spain (15), Sweden (8), Switzerland (2), United Arab Emirate (1) United Kingdom (8) and Venezuela (1). Post EMA: 37 investigational sites treated 1375 patients in 5 countries (India, Korea, Philippines, Switzerland and Vietnam). Methodology: The study was a prospective, international, non-interventional cohort comparison of rivaroxaban vs. any other pharmacological standard treatment for the prophylaxis of VTE after major orthopedic surgery. Indication/ Main Inclusion Criteria: Study Objectives: Patients were followed from the time when VTE prophylaxis treatment was initiated up until 3 months after surgery. Data were recorded in standardized case report forms (CRFs). In some countries, an electronic data capture system (EDC) was used to record the data. The other countries used paper (CRFs). Inclusion criteria: Female and male patients aged 18 years and who were undergoing elective hip or knee arthroplasty (or hip fracture surgery where indicated) and receiving rivaroxaban or other pharmacological standard treatment for VTE prophylaxis. Note: the regulatory approval in Switzerland for rivaroxaban includes fracture related surgery. Exclusion criteria: In conjunction with the local product information. Primary objective of the study was to collect data on serious and nonserious adverse events (AEs), such as: Bleeding events Any symptomatic thromboembolic events (e.g. deep vein thrombosis [DVT], pulmonary embolism [PE]) Uncommon AEs (event rate between 0.1% and 1%) All-cause mortality. The analysis compared The group of patients treated with rivaroxaban with the group treated with any standard VTE prevention therapy (called standard of care group). Page 2 of 6

4 Evaluation Criteria: Statistical Methods: Main: Bleeding events reported as serious or non-serious AEs. Symptomatic thromboembolic events reported as serious or non-serious AEs. The analysis was performed on the full safety analysis set, defined as all patients who: took at least one dose of a VTE prophylactic drug. Patients were assigned to the analysis groups according to the initially used post-surgery VTE prophylactic drug. The EMA analysis was performed on the safety analysis set (17,413 patients). The propensity score method was used to derive an analysis population with balanced baseline covariates (16,516 adjusted full safety sets). For the post EMA analysis the safety analysis set consisted of 1,353 patients All issues concerning patient data consistency checks, permissible data modifications, and coding of medical terms and concomitant medication were described in detail in the Data Management Plan. Particularly, the classification of major and non-major bleeding events was described in the Database Structure. All statistical issues including calculated variables are detailed in the Statistical Analysis Plan (SAP). Safety: All AEs as well as treatment-emergent AEs were evaluated. Treatment-emergent events were defined as events that started on or after the day of the first dose of a VTE prophylactic drug and up to 2 days after the last dose. All patients with AEs were listed with all details from the AE report form and coded according to Medical Dictionary for Regulatory Activities (MedDRA), version 14.0 (EMA analysis) or 15.1 (post EMA), with preferred term (PT) and system organ class (SOC). Patients who died were listed with type and duration of VTE prophylaxis, concomitant medication (including indication) as well as details from all reported AEs. Bleeding events were a subset of AEs and after documentation they were differentiated automatically between major and non-major bleeding events according to two different systems definitions of major bleeding: the adjudication rules as used in the phase III study RECORD 1 (NCT ) The European Medicines Agency (EMA) guideline on clinical investigation of medical products for prophylaxis of high intraand post-operative venous thromboembolic risk. The EMA definition is similar to the phase III study major bleeding definition but with the inclusion of bleeding warranting treatment cessation and surgical-site bleeding events associated with a fall in hemoglobin of 2 g/dl or leading to a transfusion of 2 units of blood or packed cells. Thromboembolic events were a subset of AEs and were reviewed by the Executive Steering Committee in a blinded manner and classified as symptomatic or asymptomatic events. All three types of thromboembolic events were analyzed: Total thromboembolic events (i.e. symptomatic and asymptomatic thromboembolic events) Symptomatic thromboembolic events Page 3 of 6

5 Asymptomatic thromboembolic events Symptomatic thromboembolic events were grouped in arterial or venous events. Number of Subjects: In the worldwide analysis (i.e. EMA analysis), XAMOS enrolled a total 17,701 patients of which the safety analysis set consisted of 17,413 patients. Note: Post-EMA patients were not included in the worldwide analysis. Results Summary Subject Disposition and Baseline Post EMA, a total of 1,375 patients were enrolled in this study. The safety analysis set consisted of 1,353 patients. Study Results For EMA analysis worldwide, a total of 17,413 patients were included in the safety analysis. Of these, 8,778 patients received rivaroxaban and 8,635 standard of care. Standard of care consisted of 81.7% LMWH, 7.9% fondaparinux, 5.5% dabigatran, 1.8% ASA, 1.4% UFH, 0.7% unspecified herbal preparation, 0.5% other prophylactic agents, and 0.5% VKA. The median age was 66.0 years in rivaroxaban and 68.0 years in standard of care patients. The majority of patients were female (62.7% in rivaroxaban, 63.0% in standard of care patients). The median BMI was 27.5 in rivaroxaban and 27.5 in standard of care patients. At inclusion to the study, total hip arthroplasty, total knee arthroplasty and other types of surgery were performed in 53.4% of rivaroxaban and 53.7% of standard of care patients, 44.8% of rivaroxaban and 44.6% of standard of care patients and 1.8% of rivaroxaban and 1.7% of standard of care patients, respectively. Median duration of VTE prophylaxis was 33.0 days in rivaroxaban-treated patients and 32.0 days in standard of care treated patients. Post EMA, a total of 1,353 patients were included in the safety analysis. Of these, 689 patients received rivaroxaban and 664 standard of care. Standard of care consisted of 68.8% LMWH, 17.8% ASA, 10.1% fondaparinux, 1.2% unfractionated heparin (UFH) and 1.1% dabigatran. The median age was 63.0 years in rivaroxaban and 64.0 years in standard of care patients. The majority of patients were female (68.4% in rivaroxaban, 70.3% in standard of care group). The median BMI was 26.7 in rivaroxaban and 26.2 in standard of care patients. At inclusion to the study, total hip arthroplasty, total knee arthroplasty and other types of surgery were performed in 20.0% of rivaroxaban and 24.2% of standard of care patients, 59.5% of rivaroxaban and 57.4% of standard of care patients and 20.5% of rivaroxaban and 18.4% of standard of care patients, respectively. Median duration of VTE prophylaxis was 15.0 days in both rivaroxaban-treated patients and those receiving standard of care. Page 4 of 6

6 Results Summary EMA analyses The incidence of treatment emergent major bleeding (RECORD) was low and similar between the treatment groups with 0.4% in rivaroxaban patients (35/8778) and 0.3% in standard of care patients (29/8635) (OR 1.19, 95%CI [0.73; 1.95]; HR 1.10, 95% CI [0.673; 1.803]) (Abbreviations: OR-odds ratio, HR-Hazard ratio, CI-confidence interval). The analyses in the propensity score adjusted population showed no qualitative and statistical differences in the point estimates of the OR or HR for RECORD major bleeding (OR 1.35, 95% CI [0.94, 1.93]; HR1.33, 95% CI [0.79, 2.25]). In addition, treatment emergent major bleeding according to the EMA definition occurred in 1.7% of rivaroxaban patients (149/8778) and 1.4% of standard of care patients (124/8635) (OR 1.19, 95% CI [0.93; 1.51]; HR 1.16, 95% CI [0.91; 1.47]). In the propensity score adjusted population, the broader definition of EMA major bleeding showed a statistical significance between rivaroxaban patients compared with standard of care patients in the OR, but not in the HR (OR 1.21, 95% CI [1.01, 1.45]; HR 1.19, 95%CI [0.92, 1.53]). The incidence of bleeding leading to treatment cessation only (as a component of EMA major bleeding) was higher in patients receiving rivaroxaban (0.4% vs 0.2%) in the safety population and the propensity score adjusted safety population. Any treatment emergent bleeding occurred more frequently in the rivaroxaban group compared with the standard-of-care group in both safety (rivaroxaban 4.7 % [410/8778]; standard of care 3.2 % [280/8635]; OR 1.46, 95% CI [1.25; 1.71]; HR 1.43, 95% CI [1.23; 1.68]) and propensity score adjusted safety populations (OR 1.50, 95% CI [1.34; 1.68]; HR 1.46, 95% CI [1.24; 1.72]. The number of patients with any symptomatic thromboembolic events was lower in the rivaroxaban group (0.9 %; 78/8778) compared to the standard of care (1.4 %; 117/8635) groups with a statistically significant risk reduction for any symptomatic thromboembolic events (OR 0.65, 95% CI [0.49; 0.87]; HR 0.61, 95% CI [0.44; 0.85]). Overall, the analyses in the propensity score adjusted population were consistent with the findings of the first analyses (OR 0.69, 95% CI [0.54; 0.79]; HR 0.65, 95% CI [0.45; 0.92]). The hip and knee subgroup analyses demonstrated the same pattern. The results of this NIS confirm the efficacy and safety results of rivaroxaban under real-life treatment conditions compared to the current pharmacological standard VTE- prophylaxis. Post EMA analyses RECORD major bleeding occurred at 0.1% (1/689) with rivaroxaban and 0.3% (2/664) with standard of care; and EMA major bleeding at 1.2% (8/689) with rivaroxaban and 0.6% (4/664) with standard of care. Any treatment-emergent bleeding events (composite of non-major and major bleeding) occurred in 2.0% treated with rivaroxaban and 1.4% receiving standard of care. Any symptomatic thromboembolic events occurred in 0.9% of the rivaroxaban group (6/689) and in 0.2% of the standard of care group (1/664). Results Summary Safety Page 5 of 6

7 EMA analyses Rivaroxaban was a well-tolerated and safe VTE prophylaxis in patients undergoing major orthopedic surgery of the hip or knee. The nature and frequency of reported AEs were similar to the standard of care. Treatment-emergent AEs were reported in 2196 (25.0 %) and 2044 (23.7 %) patients receiving rivaroxaban and standard of care treatments, respectively. Treatment-emergent serious AEs (SAEs) were reported in 689 (4.0%) patients (rivaroxaban group: n=351 [4.0%]; standard of care group: n=338 [3.9%]). Study drug related serious adverse events (SAEs) were reported in 156 (0.9 %) patients (rivaroxaban group: 91 [1.0 %] patients; standard of care group: 65 [0.8 %] patients). Twenty-five patients (12 patients [rivaroxaban group], 13 patients [standard of care group]) died during the course of the study. Subgroup analyses consistently demonstrated that overall, there were no relevant differences between the hip and knee subgroups with regards to AEs. No new safety signal was detected. The results of this NIS confirm the safety results of rivaroxaban under real-life treatment conditions compared to the current pharmacological standard VTE- prophylaxis. Post EMA analyses Treatment-emergent AEs were reported in 109 (15.8%) and 112 (16.9%) patients receiving rivaroxaban and standard of care, respectively. Treatment-emergent serious AEs (SAEs) were reported in 42 (3.1%) patients (rivaroxaban group: n=17 [2.5%]; standard of care group: n=25 [3.8%]). No patients treated with rivaroxaban, but 2 (0.3%) patients receiving standard of care, died during the course of the study. Conclusion(s) The results of this NIS confirm the efficacy and safety results of rivaroxaban under real-life treatment conditions compared to the current pharmacological standard VTE- prophylaxis. Rivaroxaban was a well-tolerated VTE prophylaxis in patients undergoing major orthopedic surgery of the hip or knee. The nature and frequency of reported AEs were similar to the standard of care. No new safety signal was detected. The benefit-risk evaluation of rivaroxaban remains unchanged and favorable. In the post EMA group, the low number of patients limits this subanalysis to an exploratory, descriptive nature and no statistical significance of findings can be derived. Within these limitations, the results from XAMOS post EMA analyses were in line with the worldwide results (EMA analyses). Publication(s): Alexander G. G. Turpie, Sylvia Haas, Reinhold Kreutz, Lorenzo G. Mantovani, Cassandra W. Pattanayak, Gerlind Holberg, Waheed Jamal, AndréSchmidt, Martin van Eickels, Michael R. Lassen; A noninterventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment; Thromb Haemost 2014; 111 (2): epublished ahead of print: doi: /th Date Created or Date Last Updated: [Mandatory field.] 04 Apr 2014 Date of Clinical Study Report: EMA analysis: 10 Oct 2012 Post EMA: 13 Aug 2013 Page 6 of 6

8 Appendix to Clinical Study Synopsis Product Identification Information Product Type US Brand/Trade Name(s) Brand/Trade Name(s) ex-us Generic Name Main Product Company Code Drug Xarelto Xarelto rivaroxaban BAY Other Company Code(s) Chemical Description Other Product Aliases IUPAC Name: 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4- morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2- thiophenecarboxamide Date of last Update/Change: 04 Mar 2013

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

Randomized, double-blind, parallel-group, multicenter, doubledummy

Randomized, double-blind, parallel-group, multicenter, doubledummy ABOUT RECORD STUDIES FAST FACTS RECORD is a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism (VTE)

More information

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM

Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism ERRATUM This report was commissioned by the NIHR HTA Programme as project number 12/78

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

More information

Clinical Study Synopsis

Clinical Study Synopsis Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace

More information

About the RECORD Clinical Trial Program

About the RECORD Clinical Trial Program About the RECORD Clinical Trial Program Fast facts RECORD was a global program of four trials in more than 12,500 patients, comparing Xarelto (rivaroxaban) and enoxaparin in the prevention of venous thromboembolism

More information

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms

More information

CDEC FINAL RECOMMENDATION

CDEC FINAL RECOMMENDATION CDEC FINAL RECOMMENDATION RIVAROXABAN (Xarelto Bayer Inc.) New Indication: Pulmonary Embolism Note: The Canadian Drug Expert Committee (CDEC) previously reviewed rivaroxaban for the treatment of deep vein

More information

ABOUT XARELTO CLINICAL STUDIES

ABOUT XARELTO CLINICAL STUDIES ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

Breadth of indications matters One drug for multiple indications

Breadth of indications matters One drug for multiple indications Breadth of indications matters One drug for multiple indications Sylvia Haas, MD, PhD Formerly of the Technical University of Munich Munich, Germany Disclosures: Sylvia Haas 1 Novel oral anticoagulants:

More information

Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip

Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Cost Effectiveness of Apixaban (Eliquis ) for the Prevention of Venous Thromboembolic Events in Adult Patients who have Undergone Elective Total Hip Replacement or Total Knee Replacement National Centre

More information

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily

More information

2. Background This indication of rivaroxaban had not previously been considered by the PBAC.

2. Background This indication of rivaroxaban had not previously been considered by the PBAC. PUBLIC SUMMARY DOCUMENT Product: Rivaroxaban, tablets, 15mg and 20mg, Xarelto Sponsor: Bayer Australia Ltd Date of PBAC Consideration: March 2013 1. Purpose of Application The application requested the

More information

Thrombosis and Hemostasis

Thrombosis and Hemostasis Thrombosis and Hemostasis Wendy Lim, MD, MSc, FRCPC Associate Professor, Department of Medicine McMaster University, Hamilton, ON Overview To review the important developments in venous thromboembolism

More information

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC

rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC rivaroxaban 15 and 20mg film-coated tablets (Xarelto ) SMC No. (755/12) Bayer PLC 13 January 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS

More information

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery

XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery XARELTO (rivaroxaban tablets) in Knee and Hip Replacement Surgery Fast Facts: XARELTO is a novel, once-daily, oral anticoagulant recently approved in the United States for the prevention (prophylaxis)

More information

The New Oral Anticoagulants. Yes

The New Oral Anticoagulants. Yes Improving Improving protection protection against against venous venous thromboembolism thromboembolism with new oral anticoagulants with new oral? anticoagulants? The New Oral Anticoagulants will replace

More information

New Oral Anticoagulants. How safe are they outside the trials?

New Oral Anticoagulants. How safe are they outside the trials? New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Total Domestic Factoring FCI 594, , , , , , , %

Total Domestic Factoring FCI 594, , , , , , , % Accumulative Turnover Figures for All FCI Members Compared to Worldwide Factoring Turnover (in Millions of EUR and USD) EUR EUR EUR EUR EUR EUR EUR INCREASE 2006 2007 2008 2009 2010 2011 2012 2011/2012

More information

Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit

Published 2011 by the American Academy of Orthopaedic Surgeons 6300 North River Road Rosemont, IL 60018. AAOS Clinical Practice Guidelines Unit Volume 4. AAOS Clinical Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty Comparison with Other Guidelines Disclaimer This clinical guideline

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 March 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 March 2010 ARIXTRA 1.5 mg/0.3 ml, solution for injection in pre-filled syringe Box of 2 (CIP: 363 500-6) Box of

More information

World Consumer Income and Expenditure Patterns

World Consumer Income and Expenditure Patterns World Consumer Income and Expenditure Patterns 2014 14th edi tion Euromonitor International Ltd. 60-61 Britton Street, EC1M 5UX TableTypeID: 30010; ITtableID: 22914 Income Algeria Income Algeria Income

More information

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason

Xarelto (Rivaroxaban): Effective in a broad spectrum. Joep Hufman, MD Medical Scientific Liason Xarelto (Rivaroxaban): Effective in a broad spectrum Joep Hufman, MD Medical Scientific Liason Xarelto : Effective in a broad spectrum Introduction Therapeutic areas SPAF VTE Prevention VTE treatment Practical

More information

Licence for use in the UK is expected before the end of 2011

Licence for use in the UK is expected before the end of 2011 News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012

Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present

More information

Σάββας Σουρμελής Διευθυντής Β Ορθοπαιδικής Κλινικής ΔΘΚΑ «Υγεία»

Σάββας Σουρμελής Διευθυντής Β Ορθοπαιδικής Κλινικής ΔΘΚΑ «Υγεία» Σάββας Σουρμελής Διευθυντής Β Ορθοπαιδικής Κλινικής ΔΘΚΑ «Υγεία» 193s Heparin 194s 198s Low-molecularweight heparin Vitamin K antagonists 199s Direct thrombin inhibitors 22 Indirect Xa inhibitor 24 Oral

More information

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES TITLE: Low Molecular Weight Heparins versus New Oral Anticoagulants for Long-Term Thrombosis Prophylaxis and Long-Term Treatment of DVT and PE: A Review of the Clinical and Cost-Effectiveness DATE: 06

More information

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto

Failure or significant adverse effects to all of the alternatives: Eliquis and Xarelto This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal DOI: 10.3310/hta13suppl3/07 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal M Stevenson,* A Scope, M Holmes,

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

Therapeutic Class Overview Oral Anticoagulants

Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview/Summary: The oral anticoagulants, dabigatran etexilate mesylate (Pradaxa ), rivaroxaban (Xarelto ), and warfarin (Coumadin, Jantoven

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

Foreign Taxes Paid and Foreign Source Income INTECH Global Income Managed Volatility Fund

Foreign Taxes Paid and Foreign Source Income INTECH Global Income Managed Volatility Fund Income INTECH Global Income Managed Volatility Fund Australia 0.0066 0.0375 Austria 0.0045 0.0014 Belgium 0.0461 0.0138 Bermuda 0.0000 0.0059 Canada 0.0919 0.0275 Cayman Islands 0.0000 0.0044 China 0.0000

More information

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime

More information

Appendix 1: Full Country Rankings

Appendix 1: Full Country Rankings Appendix 1: Full Country Rankings Below please find the complete rankings of all 75 markets considered in the analysis. Rankings are broken into overall rankings and subsector rankings. Overall Renewable

More information

A patient's guide. Your clinic's contact details are: Name: Contact number:

A patient's guide. Your clinic's contact details are: Name: Contact number: A patient's guide Your clinic's contact details are: Name: Contact number: Contents 2 Why have I been prescribed Xarelto? 2 What is Xarelto? 3 How do I take Xarelto? 3 What should I do if I miss a dose

More information

rivaroxaban 15mg and 20mg film-coated tablets (Xarelto ) SMC No. (852/13) Bayer plc

rivaroxaban 15mg and 20mg film-coated tablets (Xarelto ) SMC No. (852/13) Bayer plc rivaroxaban 15mg and 20mg film-coated tablets (Xarelto ) SMC No. (852/13) Bayer plc 08 February 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises

More information

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients

Prescriber Guide. 20mg. 15mg. Simply Protecting More Patients. Simply Protecting More Patients Prescriber Guide 20mg Simply Protecting More Patients 15mg Simply Protecting More Patients 1 Dear Doctor, This prescriber guide was produced by Bayer Israel in cooperation with the Ministry of Health as

More information

National Guidance and New Protocols

National Guidance and New Protocols National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 DVT patient pathway Assessment Diagnosis

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

Reporting practices for domestic and total debt securities

Reporting practices for domestic and total debt securities Last updated: 4 September 2015 Reporting practices for domestic and total debt securities While the BIS debt securities statistics are in principle harmonised with the recommendations in the Handbook on

More information

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther

New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,

More information

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation

EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention in Patients with Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com EMA Reaffirms Positive Benefit-Risk Balance of Bayer s Xarelto for Stroke Prevention

More information

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S. Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint

More information

Evidence-based Synthesis Program. December 2012

Evidence-based Synthesis Program. December 2012 Department of Veterans Affairs Health Services Research & Development Service Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens in Patients Undergoing Total Hip

More information

The importance of adherence and persistence: The advantages of once-daily dosing

The importance of adherence and persistence: The advantages of once-daily dosing The importance of adherence and persistence: The advantages of once-daily dosing Craig I. Coleman, PharmD Professor, University of Connecticut School of Pharmacy Storrs, CT, USA Conflicts of interest Dr

More information

International Recruitment vs. National Recruitment. Rolf Heeb. AIMS International

International Recruitment vs. National Recruitment. Rolf Heeb. AIMS International International Recruitment vs. National Recruitment Rolf Heeb AIMS International CONTENT 1. Introduction 2. Definitions 3. Considerations in International Recruitment 4. Global Executive Search Firms 5.

More information

Anticoagulant therapy

Anticoagulant therapy Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in

More information

Prior Authorization Guideline

Prior Authorization Guideline Guideline Guideline Name Formulary Xarelto (rivaroxaban) UnitedHealthcare Community & State Approval Date 0/0/203 Revision Date 8//204 Technician Note: CPS Approval Date: /5/20; CPS Revision Date: 8/20/204

More information

International Clinical Trials and Liability Insurance - The Challenges and their Solutions. Barrie Lloyd (QBE Switzerland)

International Clinical Trials and Liability Insurance - The Challenges and their Solutions. Barrie Lloyd (QBE Switzerland) International Clinical Trials and Liability Insurance - The Challenges and their Solutions Barrie Lloyd (QBE Switzerland) Disclaimer The information contained herein has been prepared by QBE Insurance

More information

Global Effective Tax Rates

Global Effective Tax Rates www.pwc.com/us/nes Global s Global s April 14, 2011 This document has been prepared pursuant to an engagement between PwC and its Client. As to all other parties, it is for general information purposes

More information

CDEC RECORD OF ADVICE

CDEC RECORD OF ADVICE CDEC RECORD OF ADVICE RIVAROXABAN (Xarelto Bayer Inc.) Indication: Deep Vein Thrombosis Without Symptomatic Pulmonary Embolism This document summarizes the Canadian Drug Expert Committee (CDEC) response

More information

National Guidance and New Protocols

National Guidance and New Protocols National Guidance and New Protocols Dr Jane Strong Consultant Haematologist DVT clinical lead Acute VTE chair DAWN AC Twentieth User Group Meeting 8 th October 2012 Autumn dawn Restless geese take flight

More information

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015

Medication Policy Manual. Topic: Eliquis, apixaban Date of Origin: July 12, 2013. Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru313 Topic: Eliquis, apixaban Date of Origin: July 12, 2013 Committee Approval Date: July 11, 2014 Next Review Date: July 2015 Effective Date: August 1, 2014 IMPORTANT

More information

Introducing Clinical Trials Insurance Services Ltd

Introducing Clinical Trials Insurance Services Ltd Introducing Clinical Trials Insurance Services Ltd Important Staff Richard Kelly Managing Director Richard joined CTIS in 2006 having previously managed the Pharmaceutical wholesale division at Heath Lambert

More information

Clinical Trials. Local Trial Requirements

Clinical Trials. Local Trial Requirements Clinical Trials Clinical trials insurance covers the legal liabilities of the insured in respect of clinical trials for bodily injury arising from the trial. The coverage provided by Newline is on the

More information

Executive Summary. Motive for the request for advice

Executive Summary. Motive for the request for advice Executive Summary Motive for the request for advice Currently nearly 400,000 people in the Netherlands are being treated with anticoagulants of a type Vitamin K antagonists (VKAs). Although VKAs are very

More information

CMMI for SCAMPI SM Class A Appraisal Results 2011 End-Year Update

CMMI for SCAMPI SM Class A Appraisal Results 2011 End-Year Update CMMI for SCAMPI SM Class A 2011 End-Year Update Software Engineering Institute Carnegie Mellon University Pittsburgh, PA 15213 1 Outline Introduction Current Status Community Trends Organizational Trends

More information

Committee Approval Date: September 12, 2014 Next Review Date: September 2015

Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November

More information

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip. A Review of the Research for Adults

Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip. A Review of the Research for Adults Preventing Blood Clots After Hip or Knee Replacement Surgery or Surgery for a Broken Hip A Review of the Research for Adults Is This Information Right for Me? Yes, if: You are considering or planning to

More information

DVT/PE Management with Rivaroxaban (Xarelto)

DVT/PE Management with Rivaroxaban (Xarelto) DVT/PE Management with Rivaroxaban (Xarelto) Rivaroxaban is FDA approved for the acute treatment of DVT and PE and reduction in risk of recurrence of DVT and PE. FDA approved indications: Non valvular

More information

TITLE: Rivaroxaban for the Treatment of Deep Vein Thrombosis: A Review of the Guidelines

TITLE: Rivaroxaban for the Treatment of Deep Vein Thrombosis: A Review of the Guidelines TITLE: Rivaroxaban for the Treatment of Deep Vein Thrombosis: A Review of the Guidelines DATE: 04 December 2012 CONTEXT AND POLICY ISSUES Deep vein thrombosis (DVT) and acute pulmonary embolism (PE) are

More information

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser

Uncontrolled when printed. Version 1.1. Acute Sector. Lead Author/Co-ordinator: Mr Simon Barker Consultant Orthopaedic Surgeon Julie Fraser Acute Sector NHS Grampian Staff Local Treatment Protocol For Venous Thromoboembolic Prophylaxis Using Rivaroxaban 10mg Tablets In Adult Patients Undergoing Elective Hip Or Knee Replacement Surgery. Lead

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

The novel anticoagulants: entering a new era

The novel anticoagulants: entering a new era Review article Peer reviewed article SWISS MED WKLY 2009;139(5 6):60 64 www.smw.ch 60 The novel anticoagulants: entering a new era Henri Bounameaux Division of Angiology and Haemostasis, Department of

More information

European Research Council

European Research Council ERC Starting Grant Outcome: Indicative statistics Reproduction is authorised provided the source ERC is acknowledged ERCEA/JH. ERC Starting Grant: call Submitted and selected proposals by domain Submitted

More information

Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty

Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty Thrombosis Volume 2013, Article ID 762310, 5 pages http://dx.doi.org/10.1155/2013/762310 Review Article The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and

More information

Common Drug Review Pharmacoeconomic Review Report

Common Drug Review Pharmacoeconomic Review Report Common Drug Review Pharmacoeconomic Review Report August 2015 Drug rivaroxaban (Xarelto) Indication Listing request Manufacturer Treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary

More information

41 T Korea, Rep. 52.3. 42 T Netherlands 51.4. 43 T Japan 51.1. 44 E Bulgaria 51.1. 45 T Argentina 50.8. 46 T Czech Republic 50.4. 47 T Greece 50.

41 T Korea, Rep. 52.3. 42 T Netherlands 51.4. 43 T Japan 51.1. 44 E Bulgaria 51.1. 45 T Argentina 50.8. 46 T Czech Republic 50.4. 47 T Greece 50. Overall Results Climate Change Performance Index 2012 Table 1 Rank Country Score** Partial Score Tendency Trend Level Policy 1* Rank Country Score** Partial Score Tendency Trend Level Policy 21 - Egypt***

More information

Does extended use of low molecular weight heparin reduce VTE risk after abdominal surgery? Student EBM presentations

Does extended use of low molecular weight heparin reduce VTE risk after abdominal surgery? Student EBM presentations Does extended use of low molecular weight heparin reduce VTE risk after abdominal surgery? Student EBM presentations Daniel Somervell & Vicky Ewing University of Oxford October 2015 The question Scenario:

More information

BT Premium Event Call and Web Rate Card

BT Premium Event Call and Web Rate Card BT Managed Event and BT Self-Managed Event (also referred to as Express, Plus and Premium) Conference Bridge and Call for Booked Audio Conferencing Services will comprise the following for each phone-conference:

More information

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis. DEEP VEIN THROMBOSIS: TREATMENT TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide an evidenced-based approach to treatment of patients presenting with deep vein thrombosis.

More information

Long series on consumer prices data documentation

Long series on consumer prices data documentation Long series on consumer prices data documentation The BIS s data set for consumer prices contains long monthly and annual time series for 60 countries. The average length of the monthly series is close

More information

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery

Rivaroxaban (Xarelto) for preventing venous thromboembolism after hip or knee replacement surgery for preventing venous thromboembolism after hip or knee replacement surgery (riv-ah-rocks-ah-ban) Summary Rivaroxaban is an oral anticoagulant and the first direct factor Xa inhibitor. Rivaroxaban has

More information

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012

EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF. Recorded Webcast Update for Analysts and Investors March 26, 2012 EINSTEIN PE Data Summary & Perspectives on XARELTO (rivaroxaban) in ORS & NVAF Recorded Webcast Update for Analysts and Investors March 26, 2012 1 Webcast Presentation Agenda EINSTEIN PE Clinical Trial

More information

Antithrombotic therapy

Antithrombotic therapy Orthogeriatrics Clinical Summary Document Antithrombotic therapy Topics Preexisting anticoagulation and timing of surgery Reversal of anticoagulation Perioperative thromboprophylaxis When should we be

More information

Monthly Report on Asylum Applications in The Netherlands and Europe

Monthly Report on Asylum Applications in The Netherlands and Europe Asylum Trends Monthly Report on Asylum Applications in The Netherlands and Europe November 2013 2014 November 2014 Colophon Title Subtitle Author Asylum Trends Monthly Report on Asylum Applications in

More information

PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY

PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY 1 UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PARTICULAR ASPECTS OF ANTI-THROMBOTIC TREATMENT IN HIP ARTHROPLASTY ABSTRACT Ph.D student DR. TRUŞCĂ PAUL TIBERIU SCIENTIFIC COORDONATOR PROF. DR.VALENTIN

More information

The Role of the Newer Anticoagulants

The Role of the Newer Anticoagulants The Role of the Newer Anticoagulants WARFARIN = Coumadin DAGIBATRAN = Pradaxa RIVAROXABAN = Xarelto APIXABAN = Eliquis INDICATION DABIGATRAN (Pradaxa) RIVAROXABAN (Xarelto) APIXABAN (Eliquis) Stroke prevention

More information

PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center

PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent Primary Care Center Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent

More information

Know the Facts. Aon Hewitt Country Profiles can help: Support a decision to establish or not establish operations in a specific country.

Know the Facts. Aon Hewitt Country Profiles can help: Support a decision to establish or not establish operations in a specific country. Aon Hewitt Country Profiles Your eguide to employment requirements and practices Profiles for nearly 90 countries worldwide Risk. Reinsurance. Human Resources. Know the Facts Whether you are a newcomer

More information

Traditional anticoagulants

Traditional anticoagulants TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University

More information

Tble Home Team Visiting Team Home Team Visiting Team Home Team Visiting Team. Open Qualification Group A. 1st Round 2nd Round 3rd Round

Tble Home Team Visiting Team Home Team Visiting Team Home Team Visiting Team. Open Qualification Group A. 1st Round 2nd Round 3rd Round Open Qualification Group A 14th WORLD BRIDGE GAMES OPEN SERIES Group A 1 Netherlands Mexico Chile Netherlands Netherlands Denmark 2 Saudi Arabia Bosnia & Hrzna Switzerland Jordan Spain Germany 3 Korea

More information

3/3/2015. Patrick Cobb, MD, FACP March 2015

3/3/2015. Patrick Cobb, MD, FACP March 2015 Patrick Cobb, MD, FACP March 2015 I, Patrick Cobb, MD, DO NOT have a financial interest/arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict

More information

OCTOBER 2010. Russell-Parametric Cross-Sectional Volatility (CrossVol ) Indexes Construction and Methodology

OCTOBER 2010. Russell-Parametric Cross-Sectional Volatility (CrossVol ) Indexes Construction and Methodology OCTOBER 2010 Russell-Parametric Cross-Sectional Volatility (CrossVol ) Indexes Construction and Methodology SEPTEMBER 2010 Russell-Parametric Cross-Sectional Volatility (CrossVol) Indexes Construction

More information

Bios 6648: Design & conduct of clinical research

Bios 6648: Design & conduct of clinical research Bios 6648: Design & conduct of clinical research Section 1 - Specifying the study setting and objectives 1. Specifying the study setting and objectives 1.0 Background Where will we end up?: (a) The treatment

More information

July 2015. Figure 1. 1 The index is set to 100 in 2000. House prices are deflated by country CPIs in most cases.

July 2015. Figure 1. 1 The index is set to 100 in 2000. House prices are deflated by country CPIs in most cases. July 2015 Globally, house prices continue a slow recovery. The Global House Price Index, an equally weighted average of real house prices in nearly 60 countries, inched up slowly during the past two years

More information

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach.

Inpatient Anticoagulation Safety. To provide safe and effective anticoagulation therapy through a collaborative approach. Inpatient Anticoagulation Safety Purpose: Policy: To provide safe and effective anticoagulation therapy through a collaborative approach. Upon the written order of a physician, Heparin, Low Molecular Weight

More information

International Call Services

International Call Services International Call Services Affordable rates for business calls. Wherever you are in the world. We ve got plenty to say when it comes to staying in touch when you re overseas. We have agreements with 443

More information